Beyond Glycemic Management: The Pharmacist’s Role in Optimizing Cardiovascular and Renal Outcomes in People with Type 2 Diabetes

CAN-eng

$0

gratuit

CCCEP,OPQ

30 min

Diabetes,Medication Management

1.5 Credits

Suivre ce cours
APPRENDRE ENCORE PLUS

Description du cours

Optimal management of people with type 2 diabetes has increased in complexity over the last several years. The focus is not only on the management of hyperglycemia, but also on interventions that have been associated with a reduction in the development and progression of complications such as cardiovascular disease and chronic kidney disease. This program is focused on providing clinicians with a quick update on the optimal management of individuals with type 2 diabetes with chronic kidney disease or at high-risk of cardiovascular disease. This case-based practical program will provide healthcare professionals with a quick update on these topics to allow them to apply evidence-informed care in practice.

Détails du cours

Date d'expiration : 2025-10-01
Métiers: Pharmacie

Faculté

  • Ronald Goldenberg, MD, FRCPC, FACE
  • Robert Hauptman, BMSc, MD, MCFP
  • Sofia Nastis, BMSc, MD, CCFP
  • Jahan Lakhani, MD, CCFP
  • Bilal Hatoum, BSc Pharm, RPh, APA, CDE
  • Susie Jin, RPh, CDE, CRE

Accréditation

This continuing education lesson is designed primarily for pharmacists and has been accredited by the Canadian Council on Continuing Education in Pharmacy (CCCEP) for 1.5 CEU(s). CCCEP File Number: 1066-2024-3857-I-P.

This continuing educational activity has been accredited by the OPQ; 1.5 continuing education units/credits will be awarded to pharmacists who successfully complete the program. Accreditation number: 240134

Objectifs d'apprentissage

Upon successful completion of this continuing education activity, you will be better able to:

  • Analyze the components of the ABCDESSS approach in managing individuals with type 2 diabetes at high risk for cardiovascular disease
  • Create treatment plans for adults with type 2 diabetes and chronic kidney disease or cardiovascular risk factors, integrating pharmacological interventions, lifestyle modifications, and regular monitoring strategies
  • Evaluate the appropriateness of using SGLT2 inhibitors, GLP-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists in adults with type 2 diabetes and chronic kidney disease, based on current evidence and guideline recommendations
  • Apply evidence-based strategies to adjust antihyperglycemic agents and manage potential side effects in people with type 2 diabetes and varying levels of renal function

CCCEP
Accrédité
Cours

OPQ
Accrédité
Cours

Suivre ce cours